Hari Madichetty, MD
Critical Care (Intensivists) · Griffin, GANPI 1437123585
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 228 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by GSK at 44.1% of the total.
Across 228 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$880
- Grifols USA, LLC$493
- Boehringer Ingelheim$158
- Baxter Healthcare$147
- Mylan Specialty L.p.$137
- plus $884 from 23 others
What the payments were for
- Food & beverage$4,78899%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 97 | $2,131 |
| AstraZeneca | 47 | $880 |
| Grifols USA, LLC | 25 | $493 |
| Boehringer Ingelheim | 9 | $158 |
| Baxter Healthcare | 6 | $147 |
| Mylan Specialty L.p. | 7 | $137 |
| Sanofi | 5 | $136 |
| Verona Pharma, Inc. | 4 | $125 |
| Inspire Medical Systems, Inc. | 2 | $87 |
| Vapotherm Inc | 4 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $70 |
| Amgen | 2 | $39 |
| Dynavax Technologies Corporation | 1 | $33 |
| Vifor Pharma, Inc. | 1 | $30 |
| CSL Behring | 1 | $24 |
| Pulmonx Corporation | 1 | $24 |
| Shire North American Group Inc | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Gilead | 1 | $21 |
| Viatris Specialty LLC | 1 | $21 |
| Philips North America LLC | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Insmed, Inc. | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Circassia Inc. | 1 | $14 |
| Merck | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$117
How this compares
Too few critical care (intensivists) providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 534 | $394,474 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 270 | $131,067 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 77 | $40,226 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 60 | $34,457 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $27,040 |
| SymbicortBudesonide/Formoterol Fumarate | 94 | $26,355 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 665 | $21,328 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $14,865 |
| Spiriva RespimatTiotropium Bromide | 19 | $11,646 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 64 | $7,295 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,526 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $4,159 |
| Ventolin HfaAlbuterol Sulfate | 45 | $3,262 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $1,935 |
| Roflumilast | 18 | $1,010 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $2,131 | $544,932855 claims |
| Boehringer IngelheimStiolto Respimat, Combivent Respimat, Spiriva Respimat | $158 | $86,330156 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $880 | $53,395136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few critical care (intensivists) providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Other critical care (intensivists) in Griffin
- Adewumi OguntunmibiSavannah$624
- Carlos Franco-PalaciosMarietta$0
- Jared SuttonFort Gordon$0
- Neil EpperlyAugusta$0
- Seung Geun YoonMacon$0
- Craig CoopersmithAtlanta$0
- Hema BalinaMacon$0
- Cederic Pimentel-FariasAtlanta$0
- Austin DebeauxAtlanta$0
- Abdulrahman ElaborCanton$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.